SCHOTT Pharma recorded good results in the second quarter and continued its profitable growth trajectory in the fiscal year 2024.
In Q2 2024, the company’s revenues grew by 11 percent to EUR 247 million at constant currencies (Q2 2023: EUR 224 million). The company’s EBITDA declined slightly compared to the prior year as expected due to ramp-up cost from the continued investments in capacity expansion and a strong comparable base resulting in an EBITDA margin of 27.0 percent (Q2 2023: 30.7 percent) at constant currencies. Revenues and EBITDA on a reported basis were impacted by strong currency headwinds in the second quarter of 2024.
“Demand for our products has remained strong in the 2024 financial year to date,” said Andreas Reisse, CEO of SCHOTT Pharma. “This underlines not only our growth ambitions but also shows that the market dynamics are intact. Thanks to our long-standing partnerships with customers and our broad portfolio, we’re ideally positioned to benefit from the attractive injectables market.”
“We have achieved good quarterly results and are satisfied, especially with the strong momentum in revenue growth,” said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma. “This is particularly true for the high demand for our strong-margin high-value syringes, which has been a key driver of our overall growth. With the first half of the year in the books, we have increased our revenue share from HVS to 53 percent and are well on track to exceed our guidance for 2024.”
The full report is available here.